Ashton Thomas Securities LLC Boosts Stock Position in Smith & Nephew SNATS, Inc. $SNN

Ashton Thomas Securities LLC raised its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 0.9% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 55,911 shares of the medical equipment provider’s stock after buying an additional 509 shares during the period. Ashton Thomas Securities LLC’s holdings in Smith & Nephew SNATS were worth $1,713,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of SNN. Hexagon Capital Partners LLC lifted its position in Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 406 shares during the last quarter. Richards Merrill & Peterson Inc. grew its stake in Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 1,000 shares during the last quarter. Bessemer Group Inc. increased its position in Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock valued at $49,000 after buying an additional 1,701 shares in the last quarter. Banque Transatlantique SA purchased a new stake in Smith & Nephew SNATS in the first quarter valued at about $52,000. Finally, Opal Wealth Advisors LLC acquired a new stake in Smith & Nephew SNATS in the first quarter worth about $73,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Price Performance

NYSE:SNN opened at $36.46 on Friday. Smith & Nephew SNATS, Inc. has a one year low of $23.69 and a one year high of $38.79. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. The firm has a market cap of $15.88 billion, a price-to-earnings ratio of 16.88, a PEG ratio of 1.01 and a beta of 0.69. The firm’s fifty day moving average is $36.06 and its two-hundred day moving average is $31.14.

Smith & Nephew SNATS Cuts Dividend

The business also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be paid a $0.285 dividend. The ex-dividend date is Friday, October 3rd. This represents a dividend yield of 165.0%. Smith & Nephew SNATS’s dividend payout ratio is presently 41.20%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SNN. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. Canaccord Genuity Group lifted their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, August 18th. Six investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.00.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.